Zafgen nets $45 mln in Series E funds
Zafgen said Wednesday that it has closed $45 million in Series E financing. Investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients.
4 December 2013•2 mins read
